ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Characterising the phenotype and outcomes of cascade-tested relatives of probands with hypertrophic cardiomyopathy. [PDF]
Chaudhry WR +3 more
europepmc +1 more source
Amyloidogenic phenotypical variation affects post-transplant outcome of hereditary transthyretin amyloidosis: a retrospective study. [PDF]
Wilczek HE +3 more
europepmc +1 more source
Monocyte chemoattractant protein-1 from a conditioned medium of bone marrow-derived mesenchymal stem cells promotes bone regeneration by enhancing macrophage phenotype polarization. [PDF]
Hashizume K +4 more
europepmc +1 more source
ACTA1-Related Adult-Onset Scapuloperoneal Myopathy With Cores and Rods. [PDF]
Caramizaru A +10 more
europepmc +1 more source
Insights Into Macrophage Polarization and M1/M2 Balance in Diabetic Foot Ulcers. [PDF]
Zhang J +6 more
europepmc +1 more source
Generative AI Accelerates Genotype-Phenotype Characterization of a 1600-Case Leigh Syndrome Virtual Cohort from Published Literature. [PDF]
Shen L.
europepmc +1 more source

